Welcome

Friday 30 January 2015

ADHD Therapeutics Market Overview and Developments by 2020

Summary 

GBI Research has released the pharma report, "ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations" Changes in diagnostic criteria have reduced the symptom threshold for diagnosis and finally bring the acceptance of adult ADHD to the clinical setting, enabling those previously unable to obtain a diagnosis to be diagnosed for ADHD treatment. In the case of adult ADHD, 4.1% of US adults are believed to suffer from ADHD, 41.3% of these cases are classified as severe and would be eligible for therapeutic intervention.  


The current ADHD therapeutics market is flooded with generics and dominated by the use of Extended-Release (ER) stimulant drugs which have superseded short-acting, Immediate-Release (IR) formulations. With dose titration per patient, ER stimulants are usually effective in 70-90% of patients. However, all stimulants apart from Vyvanse come with potential for abuse. Non-stimulants are used for those who are poor-responders, have poor cardiac history or prefer non-stimulant medication however their efficacy is lacking in comparison. Currently, 10% of adult patients are using a combination of ER and IR treatment for an additional duration, representing an unmet need within this growing ADHD segment.  

The current developmental pipeline addresses these gaps in the market, with three potential non-stimulants entering the market during the forecast period and SHP465, which aims to address the unmet need in the adult ADHD segment with its tailored duration of action. In spite of anticipated drug approvals, patents expirations and increased generic competition will cause ACoT to remain fairly static and even decrease across some nations. 

As a result, the global market is not expected to be driven by drug approvals, but primarily by a growing prevalence, increase in rates of diagnosis, and therefore eligible treatment population. Global market revenues are forecast to rise at a CAGR of 4.8% to $9.4 billion by 2020.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Research Report - Non-Small Cell Lung Cancer Market 2020 Published By Radiant Insights

Summary 

GBI Research, a leading business intelligence provider, has released its latest research report, "Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market". The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020. This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Growth will be driven by novel therapies entering the squamous cell carcinoma market segment, which is currently lacking effective treatment, unlike the non-squamous market segment. 


The report focuses on the increasing differentiation between the three main NSCLC subtypes: squamous cell, adenocarcinoma, and large cell carcinoma. Common genetic and molecular aberrations within these histologies are being extensively researched and targeted by novel therapeutics and so the treatment algorithm between histological subtypes is forecast to become more differentiated over the forecast period. Most notably, patients with squamous cell carcinoma are set to benefit from crucial first- and second-line therapies in the form of Yervoy (ipilimumab) and nivolumab, having relied on generic chemotherapy for the past decade. Non-squamous patients, on the other hand, have several successful histology-specific therapies, such as Alimta (pemetrexed), and mutation-specific therapies, such as Tarceva (erlotinib), that are already marketed. New second-line entrants will create a crowded and competitive environment. The generic erosion of market leaders Alimta and Tarceva late in the forecast period will make this a tough environment for new products that have shown only minor improvements in safety or efficacy. 

Despite the potential of targeted therapies and the identification of several promising molecular targets, the development of these products remains in the early-stage pipeline. Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations are likely to remain the only identified intracellular molecular aberrations targeted by marketed products, both of which are mainly found in adenocarcinoma tumors. Instead, the late-stage pipeline is primarily occupied by immunotherapies, which still offer a greater degree of specificity than chemotherapies; however, they initiate tumor destruction via the immune system. Necitumumab, Yervoy and nivolumab are all Phase III immunotherapies expected to reach the market in the forecast period, each with a different target.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Transcatheter Heart Valve Industry 2020 - New Market Study Published By Radiant Insights

Summary 

GBI Research's report, "Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain)" provides quantitative analysis of the transcatheter heart valves market in Europe. The analysis includes market size data by revenue and volume over the 2007-2020 period and key company share data by revenue in 2013 for the following countries: Germany, France, Italy, UK and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. 


Scope 

- Information on market size for the transcatheter heart valves
- Annualized sales data by revenue for the 2007-2020 period and company share data by revenue for 2013
- Annualized sales data by volume for the 2007-2020 period
- Coverage of key geographies: Germany, France, Italy, UK and Spain 

Reasons to buy 

- Derive actionable insights from value-volume relationships
- Analyze value-volume relationships and provide direction to marketing and sales strategies
- Develop market-entry and market-expansion strategies
- Identify the key players best positioned to take advantage of opportunities in the European market

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Glioblastoma Multiforme Therapeutic Market Share And Forecasts To 2020

Summary 


GBI Research, the leading business intelligence provider, has released its latest research, "Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM", which provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with market forecasts until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, and in-depth analysis of the marketed and pipeline products. 

The value of the GBM market in the APAC region amounted to an estimated $49.4m in 2013, and is expected to register a Compound Annual Growth Rate (CAGR) of 11.5%, to reach $105.8m by 2020. The GBM market in India was the smallest of the APAC markets in 2013, but is expected to experience the highest growth rate in the forecast period, at a CAGR of 14.4%, due to having the highest number of promising candidates in the pipeline. Japan currently has the largest share of GBM market in the APAC region, at 48%, and is expected to experience healthy growth during the forecast period at a CAGR of 13.8%.  


The existing treatment landscape is bleak for both newly diagnosed and recurrent GBM, with temozolomide alone serving as the standard of care after surgery and radiation. For first-line treatment Rindopepimut, a novel vaccine, is in late-stage development in India and Australia, but it is limited to EGFRvIII patients. There are two strong candidates in the current pipeline for second-line treatment: Avastin and Cotara. Avastin is the first and only targeted therapy for newly diagnosed GBM, is already approved as second-line treatment in Australia and Japan, and is in Phase III development in China and India. Cotara is a single-infusion drug with a novel delivery route, which is in Phase II development in India. The expected launch of these three drugs is the key driver for growth in APAC GBM market. As all are expensive, even a modest uptake will increase the annual cost of therapy, and subsequently the market size.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Ventilators Market Analysis And Segment Forecasts To 2020 By Radiant Insights, Inc

Summary 

GBI Research's report, "Ventilators Market to 2020 - Technical Advances and Hospital Expansion Serve as Distinct Regional Growth Drivers" discusses the market, competitive landscape, and trends for three ventilator market segments: Adult/pediatric, neonatal and transport ventilators.It provides comprehensive information on the key trends affecting these segments, and key analytical content on the dynamics of the market. The report also reviews the competitive landscape, analyzes pipeline products by segmentand gives details of important merger and acquisition deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. 


Scope 

- Key geographies: US, Canada, Brazil,UK, Germany, France, Italy, Spain, Japan, China, India and Australia
- Information on market size for three ventilator market segments: Adult/pediatric, neonatal and transport ventilators
- Annualized market revenue data forecast to 2020 and company share data for 2013.
- Qualitative analysis of key trends in the ventilatorsmarket
- Information on the competitive landscape and the leading technologies of key players: ResMed, Philips Respironics, Covidien, Draegerwerk, GE Healthcare, CareFusion, Smiths medical, Fisher & Paykel Healthcare, Maquet 

Reasons to buy 

- Develop business strategies by understanding the trends and developments driving the global ventilators market
- Design and enhance your product development, marketing, and sales strategies
- Exploit merger and acquisition opportunities by identifying the market players with the most innovative pipelines
- Develop market-entry and market-expansion strategies
- Identify the key players best positioned to take advantage of the emerging market opportunities
- Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Thursday 29 January 2015

Mammography Systems Market Strategies And Forecasts 2020

Summary 

GBI Research's report, "Market Snapshot: Mammography Systems 2006 to 2020 - Americas (US, Canada, Brazil, Mexico)" provides quantitative analysis of the two mammography systems market segments: full field mammography systems and film-screen mammography systems. The analysis includes market size data by revenue and volume over the 2006-2020 period for the following countries: the US, Canada, Brazil and Mexico It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. 


Scope 

- Information on market size for the two mammography systems market segments: full field mammography systems and film-screen mammography systems
- Annualized sales data by revenue for the 2006-2020 period and company share data by revenue for 2013
- Annualized sales data by volume for the 2006-2020 period - Coverage of key geographies: the US, Canada, Brazil and Mexico 

Reasons to buy 

- Derive actionable insights from value-volume relationships
- Analyze value-volume relationships and provide direction to marketing and sales strategies
- Develop market-entry and market-expansion strategies
- Identify the key players best positioned to take advantage of opportunities in the Americas market


About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Non-Hodgkin Lymphoma Therapeutics Industry 2020 - New Market Study Published By Radiant Insights

Summary 

GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan.

It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).


The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting.

An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Acute Myeloid Leukemia Therapeutics Market Share, Size, Trends, Analysis and Forecasts To 2020 By Radiant Insights

Summary 

GBI Research, has released its latest pharma report, "Acute Myeloid Leukemia Therapeutics Market to 2020 - Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts" 

Treatment and prognosis in AML is strongly influenced by a patient's age, and their cytogenetic profile. In the majority of cases these two prognostic influences are linked, with a higher frequency of unfavorable cytogenetic abnormalities observed in the elderly. Survival in this cohort of elderly patients is very poor, with a five year overall survival of 3-8% (Luger, 2010). Despite a relatively advanced understanding of genetic abnormalities associated with AML, the introduction of targeted therapies is lagging in this indication in comparison to other cancers such as breast and lung cancer, with no approved targeted therapies. Such slow development may be a reflection of AMLs status as an orphan indication. 


Intensive treatment in eligible patients (younger patients, and approximately 50% of diagnosed elderly patients) is typically the combination of the two chemotherapeutic agents cytarabine and daunorubicin, both of which were approved in the 1960s. In patients ineligible for intensive first-line chemotherapy, options are very poor, with the more recently approved Vidaza and Dacogen as the treatment options, which both offer unsatisfactory survival. Across all newly diagnosed patients that obtain complete remission, a stem cell transplant offers the highest chance of long-term survival. However, this procedure is risky, with a higher rate of treatment related mortality in the absence of better techniques to reduce the risk of graft-versus-host disease. 

The majority of patients experience disease relapse, which is almost always fatal. Treatment options in these patients typically involve the off-label use of chemotherapeutic agents, whether in combination or as monotherapies.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Melanoma Therapeutics Market Analysis And Segment Forecasts To 2020 By Radiant Insights, Inc

Summary 

GBI Research, a leading business intelligence provider, has released its latest research report, "Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth" Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90-95% of all melanomas. 


Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth. 

Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Consequently, the melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Cardiac Rhythm Management Devices Industry 2020: Latest Market Research Analysed

Summary 

GBI Research's report, "Market Snapshot: Cardiac Rhythm Management Devices 2006 to 2020 - US and Europe (US, Germany, France, Italy, UK, Spain)" provides quantitative analysis of the four cardiac rhythm management devices market segments: : cardiac resynchronization therapy devices, implantable cardioverter defibrillators, implantable loop recorders and pacemakers. The analysis includes market size data by revenue and volume over the 2006-2020 period for the following countries: US, Germany, France, Italy, UK and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. 

Scope 

- Information on market size for the four cardiac rhythm management devices market segments: : cardiac resynchronization therapy devices, implantable cardioverter defibrillators, implantable loop recorders and pacemakers
- Annualized sales data by revenue for the 2006-2020 period and company share data by revenue for 2013
- Annualized sales data by volume for the 2006-2020 period
- Coverage of key geographies: China US, Germany, France, Italy, UK and Spain 


Reasons to buy 

- Derive actionable insights from value-volume relationships
- Analyze value-volume relationships and provide direction to marketing and sales strategies
- Develop market-entry and market-expansion strategies
- Identify the key players best positioned to take advantage of opportunities in the US and European markets

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Wednesday 28 January 2015

Market Overview - Picture Archiving and Communication Systems Industry 2020: Radiant Insights

Summary 

GBI Research's report, "Picture Archiving and Communication Systems Market to 2020 - Digitization of Healthcare Systems and Evolution of PACS as a Decision Support Tool Drive Growth" discusses the market, competitive landscape, and trends for two Picture Archiving and Communications Systems (PACS) market segments: radiology PACS and cardiology PACS. It provides comprehensive information on the key trends affecting these segments, and key analytical content on the dynamics of the overall market. The report also reviews the competitive landscape, analyzes pipeline products by segment and gives details of important Merger and Acquisition (M&A) deals. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. 


Scope 

- Coverage of key geographies: US, Canada, Brazil, UK, Germany, France, Italy, Spain, Japan, China, India and Australia
- Information on market size for two PACS market segments: radiology PACS and cardiology PACS
- Annualized market revenue data forecast to 2020 and company share data for 2013
- Qualitative analysis of key trends in the PACS market
- Information on the competitive landscape and the leading technologies of key players: GE Healthcare, Fujifilm Corporation, Philips Healthcare, Agfa Healthcare, Merge Healthcare, Cerner Corporation, McKesson Corporation, Sectra AB, Siemens Healthcare and Carestream Health

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519

Colorectal Cancer Therapeutics Market Trends And Segment Forecasts To 2020 - Radiant Insights

Summary 

GBI Research, the leading business intelligence provider, has released its latest research, "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies", which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan.

It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Colorectal Cancer (CRC). The market in the APAC region was worth an estimated $1.9 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $1.9 billion in 2020.


The use of targeted therapies is expected to increase in the Asia-Pacific (APAC) markets (for the purposes of this report, APAC refers to Australia, China, India and Japan only), as patient access to these more expensive agents improves. The moderate uptake of late-stage pipeline products panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market. Others such as ramucirumab, TAS-102, TS-1, MelCancerVac will also contribute.

An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC CRC market.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit – Radiant Insights


Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519